Summary of Terns Pharmaceuticals Conference Call Company Overview - Terns Pharmaceuticals, founded in 2017, has transitioned from a metabolic company to focus on chronic myeloid leukemia (CML) with its lead asset, TERN-701, an allosteric BCR-ABL inhibitor [3][4] Core Insights - **Efficacy of TERN-701**: Data presented at ASH showed TERN-701 achieved a 75% major molecular response (MMR) rate at 24 weeks, significantly higher than competitors [20][31]. - **Safety Profile**: TERN-701 has a differentiated safety profile with no observed signals for hypertension or pancreatic toxicity, which are concerns with other treatments like asciminib [20][70]. - **Convenience**: TERN-701 can be taken without regard to food, unlike some competitors that require fasting [3][20]. CML Market Dynamics - **Current Treatment Landscape**: CML was previously fatal before BCR-ABL inhibitors like imatinib were introduced. However, about 75% of patients become refractory to imatinib, leading to a need for better therapies [5][6]. - **Scemblix's Market Position**: Scemblix has captured about 25% of the front-line market and over 50% in second-line plus patients, being recognized as the safest therapy available [6][8]. - **Patient Population**: Approximately 17,000 new patients are diagnosed with CML annually in the G7, with an additional 13,000 in the second-line and second-line plus population [44][48]. Competitive Landscape - **Comparison with Asciminib**: TERN-701 is positioned to outperform asciminib, especially in patients who are refractory to it. The efficacy in asciminib refractory patients is seen as a key differentiator [49][60]. - **Market Potential**: Analysts estimate the market for CML treatments could reach $4 billion, with TERN-701 expected to capture significant market share due to its superior profile [65][66]. Regulatory and Development Strategy - **Pivotal Trials**: Terns is preparing for pivotal trials in the second-line plus population and is also planning a frontline study, potentially starting in 2027 [85][88]. - **Enrollment Success**: Enrollment for ongoing studies has been strong, with expectations to fully enroll the CARDINAL study this year [88]. Additional Considerations - **Patient Switching**: There is a prevalent population of about 100,000 patients who may switch to TERN-701 as better therapies become available [48]. - **Market Access Challenges**: Some patients may not have access to newer therapies due to cost concerns, with generics still playing a role in treatment decisions [68][69]. Conclusion - Terns Pharmaceuticals is well-positioned in the CML market with TERN-701, which shows promising efficacy and safety compared to existing therapies. The company is actively pursuing regulatory pathways to bring this innovative treatment to market while navigating competitive dynamics and patient access challenges.

Enliven Therapeutics FY Conference Summary Company Overview - **Company**: Enliven Therapeutics (NasdaqGS:ELVN) - **Focus**: Development of ELVN-001 for chronic myeloid leukemia (CML) - **Current Leadership**: Rick Fair (CEO), Ben Hohl (CFO) [2][5] Key Points and Arguments Current State and Strategy - Enliven is in a strong position, focusing on launching ELVN-001 into its first phase 3 study [2][3] - Strong phase 1 data has been reported, with plans to meet health authorities midyear for alignment on phase 3 study design [3][4] - The company aims to maximize the value of ELVN-001 across CML treatment lines, including front-line settings [4] Leadership Transition - Rick Fair succeeded Sam Kintz, who founded the company and focused on early-stage development [5][6] - Fair brings extensive experience in late-stage development and commercialization, particularly in cancer therapies [6][7] Clinical Data and Efficacy - Phase 1B data showed major molecular response (MMR) rates between 38% and 53% in heavily pretreated patients, indicating strong efficacy despite challenging patient demographics [9][10] - The drug is well-tolerated, with a low rate of treatment discontinuation due to adverse events (4.4%) [11][12] - Enliven believes ELVN-001 is more effective and better tolerated than existing second-generation TKIs [12][26] Competitive Landscape - Enliven positions ELVN-001 as a second-line-plus treatment, particularly for patients who have previously failed other therapies like asciminib [23][25] - The company anticipates that the competitive landscape will depend on the overall treatment profile, including efficacy, safety, and convenience [26][27] Market Opportunity - The U.S. CML market is estimated at approximately $9 billion, with a growing patient population due to improved survival rates [42][43] - Enliven aims to capture a significant share of the second-line-plus market following its pivotal trial [42] Future Plans and Regulatory Strategy - Enliven plans to conduct a second-line-plus study head-to-head against physician's choice of first and second-generation TKIs [29][30] - The company is also preparing for a phase 1 study in front-line patients to gather additional safety and efficacy data [31][32] Financial Position - Enliven has a cash balance of approximately $460 million, providing a runway into the first half of 2029, which supports ongoing development efforts [53] Pipeline and Strategic Focus - Enliven is exploring strategic alternatives for its ELVN-002 program while focusing on the promising ELVN-001 [44][46] - The company is also working on preclinical programs, particularly in Graves' disease, which could be transformative if successful [47] Important but Overlooked Content - The importance of understanding patient demographics and data maturity when interpreting MMR rates in clinical trials [54] - The potential for combining ELVN-001 with other therapies to enhance treatment outcomes and achieve deeper molecular responses [40][41] This summary encapsulates the key insights from the Enliven Therapeutics FY Conference, highlighting the company's strategic direction, clinical data, market potential, and future plans.

Core Insights - Terns Pharmaceuticals announced updated data from the CARDINAL trial of TERN-701, showing a 64% major molecular response (MMR) achievement by 24 weeks across all efficacy evaluable patients and a 75% MMR achievement at doses greater than 320mg QD [1][3][4] - The safety and tolerability profile of TERN-701 has been encouraging, with no dose-limiting toxicities observed and a majority of patients remaining on treatment [11][18] - The company will host an investor update call to discuss the findings further [1][16] Study Results - The CARDINAL trial has reported a cumulative MMR rate of 74% (28/38) by 24 weeks, with 100% of those achieving MMR maintaining it [7][12] - In difficult-to-treat patient subgroups, the MMR rates were 65% for those with prior lack of efficacy to the last TKI and 88% for those with prior tolerability issues [7][11] - The deep molecular response (DMR) achievement rate by 24 weeks was 29% (10/34) [11] Patient Cohorts - The study enrolled 63 patients as of the cutoff date, with a median of 3 prior TKIs and a significant portion having discontinued their last TKI due to lack of efficacy [6][11] - Among patients at doses ≥ 320mg QD, the overall MMR rate was 80% (24/30) by 24 weeks, with a DMR achievement rate of 36% [12][18] Safety Profile - 87% of patients remained on treatment as of the data cutoff, with discontinuations primarily due to disease progression or adverse events [11] - Most treatment-emergent adverse events were low grade, with common non-hematologic TEAEs including diarrhea (21%), headache (19%), and nausea (19%) [11][12] Future Development - Terns Pharmaceuticals plans to focus on pivotal clinical development for TERN-701 in chronic myeloid leukemia (CML) [4][5] - The company aims to advance TERN-701 as a potential best-in-disease therapy for both second-line and first-line CML treatments [4][19]

Core Viewpoint - Terns Pharmaceuticals Inc. is experiencing a significant increase in stock price following positive data from the ongoing CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML), suggesting the potential for TERN-701 to be a transformative therapy in the CML treatment landscape [1][2][3]. Group 1: Trial Data and Efficacy - The CARDINAL trial is currently in the dose-escalation and dose-expansion phases, with 55 patients enrolled as of June 30 [2]. - Among 32 efficacy-evaluable patients, the major molecular response (MMR) achievement rate at 24 weeks is reported at 64%, which is significantly higher than rates in other Phase 1 studies of CML therapies [2][3]. - The overall cumulative MMR rate is 75% (24 out of 32 patients), with 100% (10 out of 10) maintaining MMR [6]. Group 2: Market Reaction and Analyst Sentiment - TERN stock has surged by 88.67%, reaching $15.58 [4]. - William Blair has upgraded Terns to Outperform from Market Perform, highlighting the promising outcomes of the TERN-701 readout [3]. - Analyst Andy Hsieh believes that TERN-701 has the potential to significantly disrupt the current CML treatment market, which is dominated by Novartis AG's Scemblix [3].

Core Insights - Terns Pharmaceuticals announced unprecedented efficacy data from the CARDINAL trial of TERN-701, showing a 64% major molecular response (MMR) achievement by 24 weeks in a refractory chronic myeloid leukemia (CML) patient population [1][3] - The company will present these findings at the 67th American Society of Hematology (ASH) Annual Meeting on December 8, 2025, and will host an investor update call following the presentation [1][7] Efficacy Data - The CARDINAL trial reported a cumulative MMR rate of 75% (24 out of 32 patients) by 24 weeks, with 64% (14 out of 22) achieving MMR and 100% (10 out of 10) maintaining MMR [5] - In difficult-to-treat patient subgroups, MMR rates were 69% (11 out of 16) for those with lack of efficacy to the last tyrosine kinase inhibitor (TKI), 60% (6 out of 10) for patients who had prior asciminib, and 67% (8 out of 12) for those with prior asciminib/ponatinib/investigational TKI [5] Patient Population - The enrolled patients had heavily pretreated, refractory disease, with a median of 3 prior TKIs; 35% had 4 or more prior TKIs [5] - 64% of patients discontinued their last TKI due to lack of efficacy, and 13% had BCR::ABL1 mutations [5] Safety Profile - TERN-701 demonstrated an encouraging safety profile, with no dose-limiting toxicities observed during the dose escalation phase [10] - The majority (74%) of treatment-emergent adverse events (TEAEs) were low grade, with the most common TEAEs being diarrhea (22%), headache (18%), and nausea (16%) [10] Upcoming Events - The oral presentation at ASH will be led by Dr. Elias Jabbour and is scheduled for December 8, 2025, from 2:45 to 3:00 PM ET [6] - Following the presentation, Terns will host a conference call and webcast for investors at 4:30 PM ET to discuss the data and next steps in the development of TERN-701 [7]

Core Insights - Novartis received a positive opinion from the CHMP of the EMA for Scemblix (asciminib) to treat adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase across all treatment lines [1][4] Group 1: Treatment Efficacy - Scemblix showed superior major molecular response (MMR) rates compared to all tyrosine kinase inhibitors (TKIs) in the Phase III ASC4FIRST trial, achieving 67.7% MMR at week 48 versus 49.0% for investigator-selected TKIs [2][5] - At week 96, Scemblix maintained superior MMR rates of 74.1% compared to 52% for investigator-selected TKIs [7] - The treatment demonstrated fewer dose reductions and half the rate of adverse events leading to discontinuation compared to existing therapies [2][4] Group 2: Patient Impact - The availability of Scemblix is expected to provide patients with better treatment options, improving their chances of achieving key efficacy milestones while maintaining quality of life [2][3] - Approximately 50% of newly diagnosed CML patients miss treatment goals within one year, highlighting the need for more effective and tolerable treatment options [6] Group 3: Regulatory and Market Position - Scemblix is already approved in over 20 countries, including the US, Japan, and China, and is recommended by the 2025 European LeukemiaNet guidelines for newly diagnosed Ph+ CML-CP patients [3][9] - If approved by the European Commission, Scemblix will expand access to treatment for four times as many patients in Europe [6]

ELVN-001 Positioning and Market Opportunity - The BCR::ABL1 TKIs market has historically generated approximately $6 billion in combined annual sales, even with generic options available[10] - There is a potential $9 billion opportunity in the U S alone for differentiated TKIs, which is validated by the successful launch of Scemblix[10] - The U S branded CML market has the potential to reach approximately $9 billion based on historical sales, adjusted for current prevalence and pricing[28] CML Landscape and Treatment - Prior to imatinib, the annual CML survival rate was less than 20%[14] - The 10-year survival rate for CML improved from less than 20% to over 80%[14] - Approximately 30% of second-line patients switch therapy within the first year of treatment[22] - Approximately 25% of first-line patients switch therapy within the first year[22] - In Q1 2025, Novartis reported Scemblix NBRx of 40% in 2L and 10% in 1L in the U S, highlighting the need for improved treatment options across all lines of therapy[32] ELVN-001 Clinical Data and Development - In the Phase 1 trial, the overall MMR (BCR::ABL1 ≤ 0 1%) by 24 weeks was 47% (25/53)[68] - 80% of patients in the ELVN-001 Phase 1 trial remained on the study, with a median duration of exposure of 29 weeks[58, 59] - The company expects to initiate the first ELVN-001 head-to-head pivotal trial in 2026[10]

Enliven Therapeutics (ELVN) Update Summary Company Overview - **Company**: Enliven Therapeutics - **Program**: ELVN001, targeting chronic myeloid leukemia (CML) Industry Context - **Market Size**: CML represents a large market with significant unmet needs, with a potential $9 billion opportunity in the U.S. alone [doc id='45'] - **Current Treatment Landscape**: The treatment of CML has evolved, focusing on quality of life and tolerability, with approximately 30% of patients switching therapies within a year due to intolerance or lack of response [doc id='7'][doc id='8'] Core Points and Arguments 1. **ELVN001's Potential**: ELVN001 is designed to address unmet needs in CML and has shown a potentially best-in-class profile in heavily pretreated patients [doc id='5'][doc id='6'] 2. **Regulatory Pathway**: Historical phase one data in CML has accurately predicted success in pivotal trials, allowing for smaller and faster studies [doc id='5'] 3. **Patient Population**: The ongoing phase one trial has enrolled a heavily pretreated population, with 72% of patients having discontinued their last TKI due to lack of efficacy [doc id='20] 4. **Efficacy Results**: - 47% of patients achieved major molecular response (MMR) by 24 weeks, with 32% achieving MMR and 100% maintaining MMR [doc id='24'] - 77% of patients achieved MR2 by 24 weeks, indicating robust efficacy despite the heavily pretreated population [doc id='25] 5. **Comparison with Osiminib**: ELVN001's efficacy appears favorable compared to osiminib, with a higher MMR rate in a more heavily pretreated population [doc id='27][doc id='36'] 6. **Safety Profile**: ELVN001 has shown a favorable safety profile, with low rates of dose reductions and discontinuations due to adverse events [doc id='31][doc id='34] 7. **Dosing Convenience**: ELVN001 supports once-daily dosing with or without food, addressing key challenges with current TKIs [doc id='34][doc id='77] Additional Important Insights - **Market Dynamics**: The CML market supports multiple blockbuster drugs despite the presence of generics, with TKI switching dynamics indicating a need for better treatment options [doc id='12] - **Emerging Competition**: Osiminib has rapidly penetrated earlier lines of therapy, but high discontinuation rates (50% within two years) indicate a significant opportunity for ELVN001 [doc id='11] - **Next Steps**: Enliven Therapeutics plans to initiate a pivotal trial for ELVN001 in 2026, with a focus on both late-line and frontline settings [doc id='16][doc id='44] Conclusion - Enliven Therapeutics is optimistic about the potential of ELVN001 to become a preferred treatment option for CML, with a clear regulatory path and promising early data supporting its efficacy and safety profile [doc id='46]